ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ARWR / insiders
CYTK (28) CORT (63) PRAX (48) TGTX (63) ⌘ Pro Terminal →

Arrowhead Pharmaceuticals Inc. (ARWR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$59.57 -0.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $59.40

Arrowhead Pharmaceuticals Inc. (ARWR) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $8.46B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ARWR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ARWR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $59.57 (-0.55% 1D, market cap $8.46B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ARWR ranks #181 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ARWR compare to CYTK and CORT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARWR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 11.1%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and CORT (Corcept Therapeutics Incorporated) posts a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ARWR?
▼

Per ARWR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000879407), Arrowhead Pharmaceuticals Inc. generated $829.4M in revenue (+23258.2% YoY), -$1.6M in net income, and $156.9M in free cash flow against $1.60B in total assets and $375.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $59.40 (-0.29%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 18.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510058
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D+ · Rk D+
Cash (17)Whales (5)SEC (16)Macro (7)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
$100 Bull$60 Base$46 Bear
📬 FREE ARWR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ARWR)Realized 20D OHLCV Swing Band: ±7.4%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY ARWR SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 18.9% FCF Margin ($156.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (28% of score)

Altman Z-Score 6.60 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
50
Grade C-$58.37+0.8% Next Q
Q2 (-2Q)
53
Grade C-$58.84+2.3% Next Q
Q3 (-1Q)
55
Grade C$60.21-1.1% Next Q
Current
58
Grade D+$59.57+0% Hist 90D α
Trajectory: C- (50) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ARWR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, ARWR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.32% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($68.15) or 200D SMA ($71.66) invalidates the momentum regime and cuts Target Base ($59.57) toward Bear Floor ($46.46).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ARWR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ARWR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 58%NO 42%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ARWR Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ARWR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ARWR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ARWR)

  • ✓Walkthrough of ARWR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ARWR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.02%📐 HORIZONTAL RANGE
2026-11-03O $60.49H $60.49L $59.57C $59.57VOL 1.12M
RES: $98.22SUP: $53.06SMA50: $68.15SMA200: $71.66
$98.75$85.23$71.71$58.19$44.67RES $98.22SUP $53.06$59.572026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ARWR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ARWR Butterfly Map → + Track ARWR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
11.2%/yr Implied 5Y Growth

vs. +23258.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ARWR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ARWR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ARWR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ARWR)

Health Care Rank #181 of 1015 ⚔️ CYTK vs ARWR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ARWR vs. CYTK, CORT, PRAX, TGTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Arrowhead Pharmaceuticals Inc. (ARWR) ranks #181 by composite RQD confidence (58/100, grade D+) and #124 by equity capitalization ($8.46B). Within this direct 5-issuer industry benchmark cohort, TGTX leads on earnings valuation at 19.9x trailing P/E, while TGTX leads on capital efficiency and profitability with 12.0% ROIC and 83.7% gross margin. CORT currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with ARWR at 58/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ARWR ACTIVE
Arrowhead Pharmaceuticals Inc.
D+ 58/100 — — 11.1% -0.55% $8.46B Benchmark Subject
CYTK
Cytokinetics Incorporated
E 28/100 — — -35.0% -1.52% $8.76B /cytk-vs-arwr →
CORT
Corcept Therapeutics Incorporated
C 63/100 93.2x 96.0% 4.8% -0.81% $8.77B /cort-vs-arwr →
PRAX
Praxis Precision Medicines Inc.
D 48/100 — — -35.0% -4.18% $7.98B /prax-vs-arwr →
TGTX
TG Therapeutics Inc.
C 63/100 19.9x 83.7% 12.0% -2.01% $9.36B /tgtx-vs-arwr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0000879407 ↗

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Arrowhead Pharmaceuticals Inc. (ARWR) reported GAAP revenue of $829.4M (+23258.2% vs. FY2024 revenue of $3.6M , and +244.5% cumulative change since FY2023) , GAAP net income of -$1.6M, operating cash flow of $179.6M, and free cash flow of $156.9M (+126.0% YoY). On the balance sheet, ARWR closed FY2025 with $1.60B in total assets against $375.4M in total debt (Altman Z-Score: 6.60, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-09-30 $829.4M -$1.6M $179.6M $156.9M $1.60B $375.4M
FY2024 (FY) 2024-09-30 $3.6M -$599.5M -$462.9M -$604.3M $1.01B $237.2M
FY2023 (FY) 2023-09-30 $240.7M -$205.3M -$153.9M -$164.7M $4.70B $1.10B

3. ARWR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ARWR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $59.57 (-0.55% 1D, market cap $8.46B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, ARWR ranks #181 in composite RQD confidence.

How does ARWR compare to CYTK and CORT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARWR carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 11.1%. By comparison, CYTK (Cytokinetics Incorporated) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $8.76B) and CORT (Corcept Therapeutics Incorporated) posts a C grade (63/100 RQD, P/E 93.2x, ROIC 4.8%, cap $8.77B). Among the 5-stock peer group, TGTX leads on earnings multiple (19.9x) while TGTX leads on capital efficiency (12.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ARWR?

Per ARWR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0000879407), Arrowhead Pharmaceuticals Inc. generated $829.4M in revenue (+23258.2% YoY), -$1.6M in net income, and $156.9M in free cash flow against $1.60B in total assets and $375.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ARWR trading relative to its 50-day, 200-day, and 52-week technical levels?

ARWR last traded at $59.57 (-0.55% on volume of 1,314,070 shares), positioning the stock -12.59% below its 50-day simple moving average ($68.15) and -16.87% below its 200-day simple moving average ($71.66). Across its 52-week range of $37.06 to $95.49, ARWR sits at the 38.5% percentile with a 14-day RSI of 41.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.4% ($55.16 to $63.98).

Direct Sub-Reports: ARWR RQD Cockpit ARWR 12M Forecast ARWR Earnings & Move ARWR Dividends & DRIP ARWR Insiders & 13F ARWR Whale Options ARWR Profit Sankey ARWR News & Why
ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ARWR — Arrowhead Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Arrowhead Pharmaceuticals Inc. (ARWR) earns a live Roarable RQD composite score of 58/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $59.57 (-0.55% 1D, market capitalization $8.46B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 11.1%, gross margin of —, operating margin of 11.9%, and free cash flow yield of 1.84%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (16/20): Incorporates a 0.96x equity beta, Altman Z-Score of 6.60, Piotroski F-Score of 8/9, and Debt/Equity of 0.57x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Arrowhead Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under Biotechnology: Pharmaceutical Preparations. The company reported revenue of $829.4M for FY 2025 after $3.6M for FY 2024, indicating a sharp change in its revenue base over the reported periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Arrowhead Pharmaceuticals Inc. (ARWR) reported $829.4M in annual revenue (up from $3.6M in FY2024, +23258.2% YoY) and -$1.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($240.7M revenue, -$205.3M net income) through FY2025, ARWR scaled operating cash flow to $179.6M and free cash flow to $156.9M, backed by $1.60B in total assets against $375.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 58/100): Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $37.06 – $95.49 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation and 73.8x EV/EBITDA against 11.9% operating margins and a 0.96x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ARWR carries a macro regime beta of 0.96 and gross margin of —.

  • Key Question #1: Can ARWR sustain or expand its 11.9% operating margin and 11.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $829.4M and free cash flow of $156.9M, how will capital allocation balance growth reinvestment against $375.4M in total debt?
  • Key Question #3: How sensitive is ARWR's 18.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.96x)?

ARWR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Arrowhead Pharmaceuticals Inc. (ARWR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ARWR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ARWR Bull vs. Bear Conversation Board — What's Your Call at $59.57?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ARWR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ARWR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $71.28 (+19.0%)
📌 Pinned Debate

Operating income swung to $98.3M in FY 2025 while debt fell from $1.10B to $375.4M, and the forensic balance sheet scores 16 of 20.

Don't sleep on ARWR's setup in Health Care. Operating income swung to $98.3M in FY 2025 while debt fell from $1.10B to $375.4M, and the forensic balance sheet scores 16 of 20.. Beta of 0.96 means it moves fast when momentum turns, and the 5-pillar RQD gauge (58/100) backs up the fundamental quality.

VolSurface_Trader 🐂 BULL

Both sides have a point here — ARWR's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $49.12 (-18.0%)
Spot @ $59.90

Net income remained negative at -$1.6M in FY 2025, the EV/EBITDA of 73.8 is high, and institutional flow scores only 5 of 20.

Here is the bear case nobody on the bull side wants to address on ARWR: Net income remained negative at -$1.6M in FY 2025, the EV/EBITDA of 73.8 is high, and institutional flow scores only 5 of 20.. At 18.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE